Chemo-Phosphoproteomic Profiling with ATR Inhibitors Berzosertib and Gartisertib Uncovers New Biomarkers and DNA Damage Response Regulators
Open Access
- 14 June 2024
- journal article
- research article
- Published by Elsevier in Molecular & Cellular Proteomics
- Vol. 23 (8) , 100802
Abstract
No abstract availableKeywords
All Related Versions
Funding Information
- Medical Research Council (MC_UU_12016/1)
- Fondation CHU de Québec
- Santé
This publication has 122 references indexed in Scilit:
- Progress towards a clinically-successful ATR inhibitor for cancer therapyCurrent Research in Pharmacology and Drug Discovery, 2021
- ATR signaling in mammalian meiosis: From upstream scaffolds to downstream signalingEnvironmental and Molecular Mutagenesis, 2020
- The identification of the ATR inhibitor VE-822 as a therapeutic strategy for enhancing cisplatin chemosensitivity in esophageal squamous cell carcinomaCancer Letters, 2018
- Multiomic Analysis of the UV-Induced DNA Damage ResponseCell Reports, 2016
- Cellular response to DNA interstrand crosslinks: the Fanconi anemia pathwayCellular and Molecular Life Sciences, 2016
- ATR inhibition rewires cellular signaling networks induced by replication stressProteomics, 2015
- Targeting Transcriptional Addictions in Small Cell Lung Cancer with a Covalent CDK7 InhibitorCancer Cell, 2014
- 53BP1 Inhibits Homologous Recombination in Brca1-Deficient Cells by Blocking Resection of DNA BreaksCell, 2010
- Expression of the C-terminal domain of novel human SR-A1 protein: Interaction with the CTD domain of RNA polymerase IIBiochemical and Biophysical Research Communications, 2005
- SQ/TQ cluster domains: concentrated ATM/ATR kinase phosphorylation site regions in DNA-damage-response proteinsBioEssays, 2005